VivoSim Labs Expands NAMkind Platform with Rat Liver Model to Bridge Human-Animal Toxicity Gap
Event summary
- VivoSim Labs plans to develop a rat liver model to complement its existing human liver platform, addressing discrepancies in toxicity translation between species.
- The new model aims to help pharmaceutical companies determine when adverse findings in rats are species-specific, reducing premature drug candidate terminations.
- Validation will use compounds with known differences in rat and human liver toxicity.
- VivoSim believes the addition will strengthen its position in liver toxicology and accelerate commercial adoption.
The big picture
VivoSim Labs' expansion into rat liver modeling addresses a critical gap in preclinical drug development, where toxicity findings in rats often fail to translate to humans. This move aligns with broader industry trends toward reducing animal testing and increasing reliance on human-relevant models, particularly as regulatory bodies like the FDA push for New Approach Methodologies (NAMs). The strategic play could position VivoSim as a key player in bridging the species divide, potentially influencing how biopharma companies assess drug candidate viability.
What we're watching
- Market Adoption
- How quickly pharmaceutical companies integrate the rat liver model into their workflows, given the industry's reliance on rat toxicology.
- Validation Success
- Whether the model's validation with known compounds will prove its reliability in differentiating human risk from rat-specific toxicity.
- Regulatory Influence
- The pace at which FDA's shift toward non-animal methods accelerates the adoption of VivoSim's NAMkind platform.
Related topics